Shares in Paris-based biotech Deinove (Euronext: ALDEI) are trading almost a tenth higher for the day on news that it has bought the Austrian firm Biovertis, through a ‘contribution in kind’ transaction valued at around 900,000 euros ($1.1 million).
.
Biovertis owns German company Morphochem, whose antibiotic candidate MCB3837 is about to enter Phase II testing as a treatment for severe clostridium difficile gastrointestinal infections (CDI).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze